Clinical Trial

Evaluation of the Efficacy and Safety of Oral LW402 Tablets for the Treatment of Patients With Moderate-to-Severe Atopic Dermatitis

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This Phase 3, double-blind (sponsor-open), multicenter, placebo-controlled study aims to evaluate the efficacy and safety of oral LW402 tablets in patients with moderate to severe atopic dermatitis.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-19.
Trial Details
NCT Number NCT07370909
Lead Sponsor Shanghai Longwood Biopharmaceuticals Co., Ltd.
Collaborators: Tigermed Consulting Co., Ltd
Conditions Moderate to Severe Atopic Dermatitis
Enrollment 480 participants
Start Date 2026-01-30
Primary Completion 2028-03-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-29